While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations.[38040] Entrada shares subsequently tumbled more than 50% after the disappointing results were released.[38040] Entrada Therapeutics' next-generation drug for Duchenne muscular dystrophy disappointed in an early trial, raising questions about the company's competitiveness in an increasingly crowded field.[36831]